Complement activation is a major inflammatory process whose primary functions are to assist in removing micro-organisms and cellular debris and 
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inhibitor of early complement activation. The APP/sCrry mice had a two-to three-fold increase in cortical and hippocampal Aβ deposition, together with a 50% loss of pyramidal neurons in region CA3 of the hippocampus.
The authors concluded that complement activation may protect against Aβ-induced neurotoxicity. Some subsequent investigations in animal models of AD have also suggested a neuroprotective role for complement in AD; Maier et al., 28 using C3-deficient APP mice, found a beneficial role for C3 in plaque clearance, and Zhou et al. 29 found evidence for both detrimental and protective effects of complement in APPQ-/-(C1q-deficient) mice. However, Pillay et al. 30 found that intracranial administration of vaccinia virus complement control protein, which inhibits both the classic and alternative complement pathways, significantly reduced memory deficits in APP mice.
The relevance of these findings to AD is unclear, because full activation of complement has not been reported in the APP mouse. One reason for this difference from the AD brain is that mouse C1q binds less efficiently than human C1q to human Aβ, resulting in less activation of mouse complement by the human Aβ present in plaques in the APP mouse. 31 Lack of appropriate anti-sera for detecting the mouse MAC may be an additional reason why the MAC has not been detected in these animals. Thus, because the main neurotoxic component of complement activation, the MAC, is apparently lacking in these mice, the balance between complement's neuroprotective and neurotoxic effects may be different in APP mice than in AD patients. and in subjects with mild cognitive impairment (MCI), a transitional state between the cognitive levels in normal (non-cognitively impaired) aged subjects and those with dementia. Plaque-associated MAC staining was only slightly increased in the frontal gyrus in these individuals and was far less than in AD patients, although total plaque numbers were similar between the two groups. 32 Zanjani et al. 33 subsequently found that early complement activation (C4d) on plaques in the temporal cortex increased in association with total plaque numbers from very mild to severe clinical AD. The MAC was detected on plaques and NFTs in some very mild cases but consistently only in severe AD. A recent study from the author's laboratory 34 measured plaque-associated complement staining in the inferior temporal cortex from aged normal, MCI, and AD patients. Earlystage (iC3b) and late-stage (C9) complement activation was found in low numbers on plaques in both aged normal individuals and subjects with MCI; total and complement-stained plaque numbers did not differ between these two groups and were 2.5-to three-fold less than in subjects with AD. Plaque complement staining was highly correlated with total plaque counts, and both of these parameters were inversely associated with measures of cognition. The authors performed regression analysis in an effort to determine the extent to which plaque-associated complement activation might contribute to cognitive deficits, but the analysis failed because of the strong correlation ('multicolinearity') between total plaque counts and complement-stained plaques. So, although complement activation increases in parallel with plaque counts during clinical progression from normal cognition (in aged subjects) to AD dementia, its role in this cognitive loss remains unclear. 
Conclusions
• Complement activation is a major inflammatory process that co-localizes with neuropathological structures in the AD brain, and progressively increases as this pathology becomes more extensive. It does not appear to be increased in the brains of individuals with MCI, however.
• Despite extensive investigation, the significance of this process in the development and progression of AD is unclear, because it exerts both neuroprotective and neurotoxic effects in vitro. Studies in animal models of AD have not succeeded in resolving this problem.
• A clinical trial in which a selective inhibitor of late-stage complement activation would be administered to AD patients should be considered. ■
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gratefully acknowledged. The objective of this study was to determine the relationship between complement activation and cognition during the development of Alzheimer's disease (AD). iC3b, C9, Bielschowsky, and Gallyas staining was performed on aged normal (n=17), mild cognitively impaired (n=12), and AD (n=17-18) inferior temporal gyrus specimens. Plaques were counted in 10x fields with high numbers of Bielschowsky-stained plaques. One-way ANOVA was used to determine between-group differences for plaque counts and measures of cognitive function, and linear regression was used to evaluate global cognition as a function of Bielschowsky-stained plaques. Terms for iC3b-and C9-stained plaques were then added sequentially as additional predictors in a 'mediation analysis' model. Complement was detected on plaques in all groups, and on neurofibrillary tangles only in AD specimens. iC3b, C9, and Bielschowsky-stained plaque counts increased 2.5-to threefold in AD versus other groups (all p ≤0.01). C9 staining was present on some diffuse plaques, and as on neuritic plaques. Bielschowskystained and complement-stained plaque counts were highly correlated, and were negatively correlated with cognitive measures.
When the Bielschowsky plaque count was used as a predictor, its correlations with cognitive measures were statistically significant, but when iC3b and C9 plaque counts were added as additional predictors, these correlations were not significant. This was attributed to multicollinearity, i.e. both early-stage (iC3b) and late-stage (C9) complement activation occurs on neocortical plaques in subjects across the cognitive spectrum; contrary to previous reports, C9 is 
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